Abstract. The role of Ras-related protein Rab23 in tumors has attracted increasing attention in recent years; however, whether it can function as an oncogenic protein remains under debate, and its role in colorectal cancer (CRC) is currently unknown. In the present study, high expression of Rab23 in CRC tissues was confirmed using immunohistochemistry, and high expression of Rab23 in CRC cells (SW1116 and HT29) was confirmed using reverse transcription-polymerase chain reaction and western blot analysis. A positive association of Rab23 with tumor size and advanced clinical stage was confirmed by χ 2 analysis. In addition, the positive association of Rab23 with poor disease-free survival was confirmed by survival analysis. Cell experiments further demonstrated that overexpression of Rab23 increased the expression of the proliferation marker Ki-67 and the proliferative ability in SW1116 and HT29 cells. Molecular mechanism research revealed that the extracellular signal-regulated kinase (ERK) and protein kinase B (AKT) signaling pathways contributed to the high expression of Ki-67 and increased the proliferative ability induced by Rab23 in CRC cells. In conclusion, the study confirmed the high expression of Rab23 in CRC, and its positive association with CRC progression and poor prognosis. Furthermore, the data demonstrated that Rab23 increased the proliferation of CRC cells via the ERK and AKT signaling pathways. These results suggest that Rab23 may be used as a protein for diagnosis and prognosis prediction in patients with CRC, and is proposed to be a novel therapeutic target for improving the patient outcome.
Introduction
Colorectal cancer (CRC) is one of the most common malignant tumors and the fourth leading cause of cancer-associated mortality worldwide (1) . In recent years, despite improvements in precancerous screening (2) (3) (4) , surgical resection (1), chemotherapy (5), radiotherapy (6) and target therapy (5), patients with CRC still exhibit poor prognosis, particularly patients at advanced stages of the disease (7) . Therefore, it is crucial to identify novel therapeutic targets to improve the prognosis of CRC patients.
Ras-related protein Rab23, a member of the Ras-related small GTPase family, was first isolated from the brain in 1994 (8) . Studies from the past three decades have demonstrated that Rab23 serves an important role in endosomal membrane trafficking (9, 10) . A further molecular mechanism study revealed that it may negatively regulate Sonic hedgehog (Shh) signaling pathway in an indirect manner (11) . In recent years, the role of Rab23 in tumors has attracted increasing attention. In 2016, Jian et al (12) reported that Rab23 promoted cutaneous squamous cell carcinoma migration and invasion via the integrin β1/Ras-related protein Rac1 pathway. In 2018, Zhang et al (13) demonstrated that Rab23 promoted the cisplatin resistance of ovarian cancer via the Shh-Gli-ATP-binding cassette sub-family G member 2 signaling pathway. However, the role of Rab23 in CRC currently remains unknown.
In the present study, it was initially confirmed that there is a high expression of Rab23 in CRC. Subsequently, it was observed that high expression of Rab23 was positively associated with tumor progression and poor prognosis. The role of Rab23 in the proliferation of CRC cells and the potential molecular mechanism were then identified.
Materials and methods
Cell culture. Human colon epithelial FHC cells, and the human CRC cell lines SW1116 and HT29 were all purchased from the American Type Culture Collection (Manassas, VA, USA). SW1116 and HT29 cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS; both from Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) (11, 12 staining. The estimated average staining intensity of positive tumor cells was represented by the intensity score, which was assigned as follows: 0, negative; 1, weak; 2, moderate; and 3, strong. The expression level of Ki-67 was evaluated using the proportion score directly, while the expression level of Rab23 was evaluated using the sum of the proportion and intensity scores, with a score of <4 indicating low expression and ≥4 indicating high expression.
Reverse transcription-polymerase chain reaction (RT-PCR).
TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) was used to extract total RNA from the samples, according to the manufacturer's protocol. The RNA concentration was measured using a 2000/2000C Ultraviolet spectrophotometer (Thermo Fisher Scientific, Inc.) cDNA was synthesized using the PrimeScript RT-PCR kit (Takara Biotechnology Co., Ltd., Dalian, China) according to the manufacturer's protocol. The PCR conditions were as follows: 25˚C for 10 min, 42˚C for 60 min and then 70˚C for 5 min. The primers used in this study were as follows: Rab23, 5'-AGG CAC TGG CAA AAA GGT YA-3' (forward) and 5'-CGG AGT GAC TTC CAC CAG AT-3' (reverse); GAPDH, 5'-AGA AGG CTG GGG CTC ATT TG-3' (forward) and 5'-AGG GGC CAT CCA CAG TCT TC-3' (reverse). GAPDH was used as an internal control.
Western blot analysis. Protein was extracted from the cells using radioimmunoprecipitation assay lysis buffer containing MTT assay. CRC cells were plated in a 96-well plate at a density of 3x10 3 cells/well. After 24, 48, 72, 96 and 120 h of incubation, the cell viability was measured by MTT assay at a wavelength of 490 nm, according to the manufacturer's protocol (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China). Growth curves were then constructed.
AKT and ERK signaling pathway inhibition. ERK inhibitor U0126 (cat. no. S1102; Selleck Chemicals, Houston, Texas, USA) or AKT inhibitor LY294002 (cat. no. S1105; Selleck Chemicals) was added to the medium of CRC cells overexpressing Rab23 at a final concentration of 10 µM/l or 50 µM/l respectively. Cell were collected at 72 h, and western blotting and MTT assay were performed as described above.
Statistical analysis. SPSS software version 13.0 (SPSS, Inc., Chicago, IL, USA) was used for statistical analysis. All data are expressed as the mean ± standard deviation. Differences between three groups were analyzed using one-way analysis of variance and Dunnett's post-hoc test, while differences between two groups were analyzed using t-test. The correlation of Rab23 with clinical parameters was analyzed using χ 2 analysis. Survival curves were constructed using the Kaplan-Meier method and compared using the log-rank test. P<0.05 was considered to denote differences that were statistically significant. Fig. 1A , strong staining of Rab23 was detected in CRC tissues, whereas almost no staining of Rab23 was observed in the non-tumor colon tissues. The difference between CRC and non-tumor tissues was statistically significant (Fig. 1B) . To further verify the expression of Rab23 in CRC, RT-PCR and western blot analyses were performed in the CRC cell lines SW1116 and HT29. The results revealed that Rab23 expression in the two CRC cell lines was significantly higher compared with that in the human colon epithelial cell line FHC, both at the mRNA (Fig. 1C and D) and protein ( Fig. 1E and F) levels. These data demonstrated that there was a high expression of Rab23 in CRC. Table I , a tumor diameter of >4 cm was only observed in 16 out of 36 cases in the low Rab23 expression group, which was significantly reduced in comparison with the number of cases with this diameter in the high Rab23 expression group (38 out of 54 cases). In addition, in the low Rab23 expression group, there were only 10 out of 36 cases at stages III/IV of the disease, which was significantly less than the cases at this stage in the high Rab23 expression group (29 out of 54 cases). However, there was no significant difference in terms of age, sex, differentiation degree and lymph node metastasis between the two groups.
Results

Rab23 is highly expressed in CRC tissues and cells. As shown in
Rab23 is positively associated with tumor size, advanced clinical stage and poor disease-free survival (DFS). As shown in
Subsequently, in order to investigate the effect of Rab23 on prognosis, survival analysis was performed.
Although the difference in overall survival (OS) between the two groups was not statistically significant, the OS of the high Rab23 expression group was poorer compared with that in the low Rab23 expression group (Fig. 1G) . In addition, the DFS of the high Rab23 expression group was significantly poorer compared with that of the low Rab23 expression group (Fig. 1H) . These results imply that Rab23 serves a role in CRC progression and prognosis. Fig. 2A , IHC staining demonstrated that tissues with high expression of Rab23 also exhibited a strong expression of Ki-67, which is known as a classical proliferation marker. The positive correlation of Rab23 and Ki-67 was found to be statistically significant (Fig. 2B) . To further confirm the effect of Rab23 on the expression of Ki-67, the expression of Rab23 in CRC cells was upregulated by plasmid transfection. Following the induction of Rab23 overexpression in SW1116 cells, the expression of Ki-67 was significantly increased at the mRNA (Fig. 2C) and protein (Fig. 2D) levels. In the CRC cell line HT29, overexpression of Rab23 also significantly increased the expression of Ki-67, both at the mRNA (Fig. 2E) and protein (Fig. 2F ) levels. These findings suggested that Rab23 may have an effect on CRC proliferation. To further test this hypothesis, an MTT assay was performed, and the result revealed that overexpression of Rab23 significantly increased the proliferative ability of SW1116 (Fig. 2G) and HT29 (Fig. 2H) cells. These results demonstrated that Rab23 can significantly increase the proliferation of CRC cells.
Rab23 increases the expression of Ki-67 and the proliferative ability of CRC cells. As shown in
ERK and AKT signaling pathways are required for Rab23
to regulate the proliferation of CRC cells. To investigate the potential molecular mechanism, possible molecular targets were detected. Subsequent to Rab23 overexpression in SW1116 (Fig. 3A) and HT29 (Fig. 3B ) cells, the phosphorylation of ERK and AKT was activated, whereas no significant changes were detected in the total ERK and AKT levels. This implied that the ERK and AKT signaling pathways could be activated by Rab23 in CRC cells.
When SW1116 (Fig. 3C) and HT29 (Fig. 3D ) cells were incubated with the ERK inhibitor U0126 or the AKT inhibitor LY294002, the increase in Ki-67 expression induced by Rab23 overexpression was reduced. Furthermore, the MTT assay revealed that incubation with U0126 or LY294002 inhibited the proliferative abilities induced by Rab23 overexpression in the SW1116 (Fig. 3E) and HT29 (Fig. 3F) cells. Taken together, these results proved that Rab23 was able to increase the proliferation of CRC cells via the ERK and AKT signaling pathways.
Discussion
Rab23 is a member of the Ras-related small GTPase family, which serves a key role in the regulation of the Shh signaling pathway. High expression of Rab23 has been reported in several types of tumors. For instance, Wang et al (16) reported that Rab23 was overexpressed in human astrocytoma, and promoted cell migration and invasion through the regulation of Rac1. Liu et al (17) also reported that Rab23 was overexpressed and activated in hepatocellular carcinoma. In the present study, high expression of Rab23 was detected in CRC tissues using IHC analysis, and this Table I . Association of Rab23 expression with the clinicopathological parameters of patients with colorectal cancer.
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Cases ( was further confirmed in CRC cells, both at the mRNA and protein levels. These results are consistent with the previously reported data by Wang et al (16) and Liu et al (17) . Thus, it is suggested that Rab23 may serve as a diagnostic marker in CRC and may function as an oncogenic protein in CRC. Thus far, the role of Rab23 has been reported in several types of tumors, but this remains under debate. Jiang et al (18) demonstrated that Rab23 promoted the proliferation and invasion of bladder cancer cells. In addition, Chang et al (19) found that Rab23 was required for tumor growth in prostate cancer. However, Liu et al (20) reported that ectopic expression of Rab23 inhibited the growth and proliferation, as well as induced cell apoptosis in breast cancer cells. In the present study, it was observed that high expression of Jiang et al (18) and Chang et al (19) , although they differ from the results of the study conducted by Liu et al (20) , and provide further evidence on the roles of Rab23 in the progression of CRC. Furthermore, the survival analysis performed in the current study demonstrated that Rab23 was positively associated with poor DFS. This is in agreement with the study by Zhang et al (13) , which reported that Rab23 was positively associated with the poor prognosis of patients with ovarian cancer, implying that Rab23 may be used for predicting the prognosis of patients with CRC.
The ERK and phosphoinositide 3-kinase/AKT signaling pathways serve an important role in a multitude of cellular functions, including cell proliferation (21), survival (22) , migration (23) , apoptosis (24, 25) and angiogenesis (15) . However, whether ERK or AKT can function as downstream targets of Rab23 remains unknown. In the present study, it was observed that overexpression of Rab23 activated the ERK and AKT signaling pathways. In addition, blocking the ERK or AKT signaling pathways eliminated the effects of Rab23 on the proliferation of CRC cells. This proved the important role of the ERK and AKT signaling pathways in the effect of Rab23 in CRC cell proliferation.
In conclusion, the present study confirmed the important role of Rab23 in CRC progression and poor prognosis, suggesting the potential use of Rab23 in diagnosis and prognosis prediction in this disease. The current study data provided a preliminary experimental basis for further research on Rab23 in CRC, and also suggested that Rab23 may serve as a novel treatment target for CRC.
